Citations 1
First-in-human, phase I study assessing imalumab (Bax69), a first-in-class anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody in advanced solid tumors.
Patel, Manish R. , Sachdev, Jasgit C. , Hart, Lowell L., Halama, Neils, Ramanathan, Ramesh K., Sarantopoulos, John , Yazji, Salim, Jaeger, Dirk, Adib, Deyaa, Kerschbaumer, Randolf J. , Mahalingam, Devalingam , Liu, Xiaochun , Tsimberidou, Apostolia M.
Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 2518-2518
